{"id":4520,"date":"2019-09-26T18:13:33","date_gmt":"2019-09-26T15:13:33","guid":{"rendered":"http:\/\/www.alfapatent-stanadvoka.com\/?p=4520"},"modified":"2021-01-12T20:54:14","modified_gmt":"2021-01-12T17:54:14","slug":"t1695-18","status":"publish","type":"post","link":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/t1695-18\/","title":{"rendered":"26.09.2019 \/T 1695\/18 \/HYPOGLYCAEMIA \/L\u00dcCK"},"content":{"rendered":"<p><a href=\"https:\/\/worldwide.espacenet.com\/publicationDetails\/originalDocument?FT=D&amp;date=20160413&amp;DB=EPODOC&amp;locale=en_EP&amp;CC=EP&amp;NR=2300008B1&amp;KC=B1&amp;ND=4\">EP 2 300 008<\/a>\u00a0numaral\u0131 patent a\u015fa\u011f\u0131daki ba\u011f\u0131ms\u0131z istemlerle tescil edilmi\u015ftir:<\/p>\n<blockquote><p>&#8220;1. Use of a liquid composition containing glycerol for preparing a medicament for reducing hypoglycemia of fasting human subjects without affecting the respiratory exchange ratio of fasting.&#8221;<\/p>\n<p>&#8220;8. A liquid composition containing glycerol for use in reducing hypoglycemia of fasting human subjects without affecting the respiratory exchange ratio of fasting.&#8221;<\/p><\/blockquote>\n<p>Daha sonra itiraza u\u011frayan patent iptal edilmi\u015f ve bu karar patent sahibi taraf\u0131ndan temyiz edilmi\u015ftir. Patent sahibi devam eden bir tecav\u00fcz davas\u0131n\u0131n varl\u0131\u011f\u0131n\u0131 gerek\u00e7e g\u00f6stererek temyiz prosed\u00fcr\u00fcn\u00fcn h\u0131zland\u0131r\u0131lmas\u0131n\u0131 talep etmi\u015f ve bu talebi kabul edilmi\u015ftir.<br \/>\n\u0130tiraz Birimi\u2019nin patenti iptal karar\u0131 \u0130stem 8\u2019deki i\u015flev s\u0131n\u0131rlamas\u0131n\u0131n (oru\u00e7 tutan kimselerde hipoglisemiyi \u00f6nlemek) tedaviye y\u00f6nelik olarak\u00a0<u>kabul edilmemesine<\/u>\u00a0dayanmaktad\u0131r. Oru\u00e7 tutan kimselerde tedaviye y\u00f6nelik olmad\u0131\u011f\u0131 kabul edilen hipoglisemi \u00f6nleme i\u015flevi, s\u00f6z konusu i\u015flevin istemi daralt\u0131yor kabul edilmemesine yol a\u00e7m\u0131\u015ft\u0131r. Bir istem t\u0131bbi endikasyon istemi olarak kabul edilirse tan\u0131mlad\u0131\u011f\u0131 i\u015flev s\u0131n\u0131rlamas\u0131 (\u00f6rne\u011fin \u00f6zel bir hastal\u0131\u011fa y\u00f6nelik olarak) \u00f6nceki teknik kar\u015f\u0131s\u0131nda yenilik sa\u011flayabilir. Ancak medikal endikasyon istemlerinde yer alan &#8220;for&#8221; kal\u0131b\u0131 ile tan\u0131ml\u0131 i\u015flevler medikal endikasyon istemi olmayan di\u011fer normal istemlerde s\u0131n\u0131rland\u0131r\u0131c\u0131 i\u015flevler olarak kabul edilmez. Bu nedenle patolojik olmayan oru\u00e7 durumunda uygulanan y\u00f6ntemin tedavi olup olmad\u0131\u011f\u0131 \u00f6nceki teknik kar\u015f\u0131s\u0131nda ayr\u0131\u015fma i\u00e7in kritik \u00f6nemdedir. \u0130tiraz birimi bunun tedavi olmad\u0131\u011f\u0131na karar vermi\u015ftir.<\/p>\n<p>Oru\u00e7 tutan kimselerdeki hipoglisemi patolojik hipoglisemi de\u011fildir. Patolojik hipoglisemide kan \u015fekeri 45 mg\/dl\u2019nin alt\u0131na d\u00fc\u015ferek terleme, \u00fc\u015f\u00fcme ve titreme e\u015fli\u011finde ileri a\u015famada \u00e7enenin kilitlenmesine yol a\u00e7an \u00e7ok ciddi bir durumdur. Ancak oru\u00e7 tutan kimselerde ortaya \u00e7\u0131kan ve patolojik olmayan hipoglisemide kan \u015fekeri 75 mg\/dl\u2019nin alt\u0131na inmemektedir.<br \/>\nTemyiz Kurulu ise patolojik hipoglisemi ile ilgili olmamas\u0131na ra\u011fmen oru\u00e7 tutan kimselerdeki hipoglisemi durumunun bir \u00e7e\u015fit tedavi ile ili\u015fkili oldu\u011fu ve \u0130stem 8\u2019deki oru\u00e7 tutan kimselerde hipoglisemiyi \u00f6nleme i\u015flevinin de \u00f6nceki teknik kar\u015f\u0131s\u0131nda s\u0131n\u0131rlay\u0131c\u0131 kabul edilmesi gerekti\u011fi g\u00f6r\u00fc\u015f\u00fcn\u00fc detayl\u0131 olarak tart\u0131\u015fm\u0131\u015ft\u0131r. Temyiz Kurulu inceleme konusu dosya kapsam\u0131ndaki literat\u00fcrde sa\u011fl\u0131kl\u0131 insanlarda d\u0131\u015far\u0131dan tetiklenen patolojik olmayan t\u00fcrde hipoglisemi i\u00e7in herhangi bir yerle\u015fik tan\u0131m veya ba\u015flang\u0131\u00e7 s\u0131n\u0131r de\u011ferleri tespit edememi\u015ftir. Bu bak\u0131mdan inceleme konusu patent tarifnamesindeki tan\u0131mlar \u00fczerinden yap\u0131lan de\u011ferlendirmede patentin patolojik olmayan hipoglisemiyi \u00f6nlemek \u00fczere ba\u015fvurdu\u011fu yolun oru\u00e7 tutan kimselere k\u0131s\u0131tl\u0131 ve d\u00fczenli bi\u00e7imde kan \u015fekerinin d\u00fc\u015fmesinin \u00f6nleyici takviyeler vermesi oldu\u011fu anla\u015f\u0131lm\u0131\u015ft\u0131r. Bu yakla\u015f\u0131m ise herhangi bir hastal\u0131\u011f\u0131 tedavi etmemekte veya herhangi bir patolojik durumun \u00f6n\u00fcne ge\u00e7memekte, sadece oru\u00e7 tutan kimselerdeki a\u00e7l\u0131k alg\u0131s\u0131n\u0131 azaltmaktad\u0131r. Bu bak\u0131mdan tedaviye y\u00f6nelik g\u00f6r\u00fclmemi\u015ftir.<br \/>\nDi\u011fer yandan \u0130stem 1\u2019deki \u0130svi\u00e7re tipi istemde tan\u0131mlanan i\u015flev (oru\u00e7 tutan kimselerde hipoglisemiyi \u00f6nlemek \u00fczere bir gliserol i\u00e7eren bir ila\u00e7 haz\u0131rlamak i\u00e7in s\u0131v\u0131 bir kompozisyon kullan\u0131m\u0131) normalde s\u0131n\u0131rlay\u0131c\u0131 yap\u0131da kabul edilir. Ancak G 1\/83, G 5\/83 ve G 6\/83 kararlar\u0131 uyar\u0131nca\u00a0<u>tedaviye y\u00f6nelik olmayan bir i\u015flev tan\u0131mlayan bir istem \u0130svi\u00e7re tipi istem yap\u0131s\u0131nda yaz\u0131lmas\u0131 sayesinde t\u0131bbi kullan\u0131m istemi yap\u0131s\u0131na b\u00fcr\u00fcnmez<\/u>.<br \/>\nSonu\u00e7 olarak iptal karar\u0131 onanm\u0131\u015ft\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>EP 2 300 008\u00a0numaral\u0131 patent a\u015fa\u011f\u0131daki ba\u011f\u0131ms\u0131z istemlerle tescil edilmi\u015ftir: &#8220;1. Use of a liquid composition containing glycerol for preparing<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[112],"tags":[],"class_list":["post-4520","post","type-post","status-publish","format-standard","hentry","category-t-kararlar"],"_links":{"self":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/comments?post=4520"}],"version-history":[{"count":3,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4520\/revisions"}],"predecessor-version":[{"id":5067,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4520\/revisions\/5067"}],"wp:attachment":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/media?parent=4520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/categories?post=4520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/tags?post=4520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}